nci-cannabisresearch (Agenda)

Agenda

Day 1 - December 15, 2020

(all times are Eastern Standard Time)

10:00 am - 10:15 am

Opening Remarks
Norman E. Sharpless, Director, National Cancer Institute (NCI), National Institutes of Health (NIH)
Robert T. Croyle, Director, Division of Cancer Control and Population Sciences, NCI, NIH

10:15 am - 10:30 am

Charge to Symposium
Gary L. Ellison, NCI, NIH

10:30 am - 11:15 am

Keynote
Cannabis Policy, Epidemiology, and Research in an Era of Legalization
Gillian Schauer, University of Washington

Session One: Non-medical Cannabis Use and Cancer Epidemiology
Co-Chairs: Gary L. Ellison, NCI, NIH and Mia Hashibe, University of Utah
11:15 am - 11:40 am Cannabis and Cancer Risk: Current Evidence and Methodological Considerations
Mia Hashibe, Huntsman Cancer Institute
11:40 am - 12:05 pm Cannabis and Tobacco Co-use: Patterns, Correlates, and Implications for Reducing Cancer Risk
Amy Cohn, Stephenson Cancer Center
12:05 pm - 12:30 pm Potentially Harmful Inhalational Exposure Resulting from Smoked and Vaped Cannabis
Benjamin Blount, Centers for Disease Control and Prevention
12:30 pm - 1:00 pm Panel Discussion
1:00 pm - 1:15 pm Break (15 min.)
Session Two: Cannabis and the Cancer Patient
Co-Chairs: Andrew N. Freedman, NCI, NIH and Ilana M. Braun, Dana Farber Cancer Institute
1:15 pm - 1:25 pm A Cancer Survivor’s Experience
Stacey Blansky
1:25 pm - 1:50 pm United States Legal Landscape for Medicinal Cannabis: ​Research & Clinical Implications
Ilana Braun, Dana Farber Cancer Institute
1:50 pm - 2:15 pm Risks of Cannabis Use for the Cancer Patient
Steven A. Pergam, Fred Hutchinson Cancer Research Center
2:15 pm - 2:40 pm Benefits of Cannabis Use for the Cancer Patient
Donald I. Abrams, University of California San Francisco (UCSF)
2:40 pm - 3:10 pm Panel Discussion

 

Day 2 - December 16, 2020

(all times are Eastern Standard Time)

10:00 am - 10:10 am Introduction and Orientation to Day 2
Session Three: Cancer Symptom/Treatment Side Effect Management – Preclinical
Co-Chairs: Yali Fu, NCI, NIH and Aron H. Lichtman, Virginia Commonwealth University (VCU)
10:10 am - 10:35 am Targeting the Endogenous Cannabinoid System to Treat Chemotherapy-induced Peripheral Neuropathy - Leads from Preclinical Studies
Aron H. Lichtman, VCU
10:35 am - 11:00 am The Endocannabinoid System and Cancer Pain
Daniele Piomelli, University of California, Irvine
11:00 am - 11:25 am Cannabinoid-based Treatment Strategies for Pain Associated with Cancer
Sara Jane Ward, Temple University
11:25 am - 11:50 am CBD Acid (CBDA) and CBDA Methyl Ester – Highly Effective Treatments for Nausea and Vomiting Using Preclinical Animal Models
Linda Parker, University of Guelph, Canada
11:50 am - 12:20 pm Panel Discussion
12:20 pm - 12:35 pm Break (15 min.)
Session Four: Cancer Symptom/Treatment Side Effect Management – Clinical
Co-Chairs: Alexis Bakos, NCI, NIH and Mark Wallace, University of California, San Diego (UCSD)
12:35 pm - 1:00 pm Cannabis and Pain Relief
Mark Wallace, UCSD
1:00 pm - 1:25 pm Cannabinoids for Cancer-Related Nausea and Vomiting
Jose M. Garcia, University of Washington
1:25 pm - 1:50 pm Cancer-Associated Anorexia and Cachexia: Defining a Palliative Role for Cannabis
Aminah Jatoi, Mayo Clinic
1:50 pm - 2:15 pm Cannabis to Enhance Well-Being: A Worthwhile Goal
Michelle Sexton, UCSD
2:15 pm - 2:40 pm The Clinician's Role in Medical Cannabis Care
Carey S. Clark, Pacific College of Health & Science
2:40 pm - 3:10 pm Panel Discussion

 

Day 3 - December 17, 2020

(all times are Eastern Standard Time)

10:00 am  – 10:10 am Introduction and Orientation to Day 3
Session Five: Cancer Biology and Prevention
Co-Chairs: Sharon Ross and Ron Johnson, NCI, NIH and Sean McAllister, Sutter Health
10:10 am - 10:35 am Cannabinoid/Cannabis Signaling and Biology
Mary Abood, Temple University
10:35 am - 11:00 am Mechanism of THC Anti-tumor Activity
Manuel Guzman, Complutense University of Madrid, Spain
11:00 am - 11:25 am Targeting Cancer with the Non-psychoactive Cannabinoid Cannabidiol
Sean McAllister, Sutter Health
11:25 am - 11:50 am Cannabinoids and HPV-mediated OroPharynx Cancer: Genes and Weed
Joseph Califano, University of California, San Diego
11:50 am - 12:20 pm Panel Discussion
12:20 pm - 12:35 pm Break (15 min.)
Session Six: Cancer Treatment – Pre-Clinical & Clinical
Co-Chairs: Jeffrey D. White, NCI, NIH and Donald I. Abrams, University of California, San Francisco (UCSF)
12:35 pm - 1:00 pm Towards the Utilization of Cannabinoids as Anti-cancer Agents
Guillermo Velasco, Complutense University of Madrid, Spain
1:00 pm - 1:25 pm Cannabinoid-mediated Novel Signaling Mechanisms in Cancer: Current Status and Future Implications
Ramesh Ganju, The Ohio State University
1:25 pm - 1:50 pm A Phase 1b Randomized, Placebo-controlled Trial of Nabiximols Cannabinoid Oromucosal Spray with Temozolomide in Patients with Recurrent Glioblastoma
Chris Twelves, University of Leeds, United Kingdom
1:50 pm - 2:15 pm Chronic Cannabis Use During Immunotherapy Treatment
Gil Bar-Sela, Emek Medical Center, Israel
2:15 pm - 2:45 pm Panel Discussion

 

Day 4 - December 18, 2020

(all times are Eastern Standard Time)

10:00 am - 10:10 am Introduction and Orientation to Day 4
Session Seven: Navigating Research Challenges for Cannabis Research
Co-Chairs: Alejandro Salicrup, NCI, NIH and Ziva D. Cooper, University of California, Los Angeles (UCLA)
10:10 am - 10:30 am Updates on the Federal Regulatory Landscape, NIH Research Portfolio on Cannabis/Cannabinoids, and the National Institute on Drug Abuse (NIDA) Drug Supply Program
Steven Gust, NIDA, NIH
10:30 am - 10:50 am Food and Drug Administration (FDA) Role in the Regulation of Cannabis Products
Douglas Throckmorton, FDA
10:50 am - 11:30 am Researchers’ Point of View Regarding Challenges and Hurdles Related to Clinical Cannabis Research
Ziva D. Cooper, UCLA and Donald I. Abrams, UCSF
11:30 am - 12:00 pm Panel Discussion
12:00 pm - 12:10 pm Break (10 min.)
Concluding Session: What’s Next?
Co-Chairs: Gary L. Ellison and Jeffrey D. White, NCI, NIH
12:10 pm - 1:30 pm Panel Discussion with All External Session Co-chairs
1:30 pm - 1:45 pm Final Comments